Bacterium, Immune Response and Licensing - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bacterium

Immune Response

Licensing

Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine

Pharmaceutical Technology

OCTOBER 28, 2022

What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20. According to the UK’s National Health Service (NHS), there are over 90 strains of this bacterium. VAX-24 met standard superiority criteria for four additional serotypes, as stated in the October 24 press release.

Vaccination

Vaccination Vaccine Marketing Bacteria

GSK bolsters vaccines division with $3.3bn swoop on Affinivax

pharmaphorum

MAY 31, 2022

In February, the company reacquired full rights to the shot from Astellas, which paid $10 million upfront to license the vaccine in 2017, clearing the way for GSK’s acquisition. The biotech says this can stimulate both B cell (antibody) and T cell immune responses with a single shot. billion in sales last year.

Vaccination

Vaccination Vaccine Bacterium Sales

Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine

GSK bolsters vaccines division with $3.3bn swoop on Affinivax

Stay Connected